Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05181215 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects
A Phase 1 study, sponsored by Banner Life Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT05181215 is a Phase 1 study that has completed, run by Banner Life Sciences. The registered enrollment target is 46 participants.
The verdict
NCT05181215, a Phase 1 study, has completed, sponsored by Banner Life Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
A single-dose, randomized, open-label, two-way crossover, two-period, two-sequence, two-treatment, single-center, bioequivalence study of Bafiertam and Vumerity.
Interventions
- DRUG Monomethyl Fumarate 190 Mg
- DRUG Diroximel Fumarate 462 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2021-05-14 |
| Est. Completion | 2021-08-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05181215
The ClinicalTrials.gov registry entry for NCT05181215 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Banner Life Sciences, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Monomethyl Fumarate 190 Mg is the first listed.
NCT05181215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05181215 about?
NCT05181215 is a clinical study titled "Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects". A single-dose, randomized, open-label, two-way crossover, two-period, two-sequence, two-treatment, single-center, bioequivalence study of Bafiertam and Vumerity.
What is the current status of trial NCT05181215?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2021-05-14. Estimated completion is 2021-08-27.
What interventions are being tested in trial NCT05181215?
The interventions under investigation include: Monomethyl Fumarate 190 Mg (DRUG), Diroximel Fumarate 462 mg (DRUG).
Who is sponsoring clinical trial NCT05181215?
This trial is sponsored by Banner Life Sciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.